GeneFerm Competitors

Stocks . Taiwan . 
Stock . GeneFerm Biotechnology Co
1796 Stock  TWD 49.95  0.45  0.89%   
GeneFerm Biotechnology competes with Taiwan Steel, WinMate Communication, China Steel, Shinkong Insurance, and Sunny Friend; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing GeneFerm Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of GeneFerm Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out GeneFerm Biotechnology Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of GeneFerm Biotechnology competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
48.1449.9551.76
Details
Intrinsic
Valuation
LowRealHigh
39.4641.2754.95
Details
Naive
Forecast
LowNextHigh
49.5551.3553.16
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
46.9648.8250.67
Details

GeneFerm Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between GeneFerm Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of GeneFerm and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of GeneFerm Biotechnology does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
8341
+ 0.81
6581
2035
+ 0.76
2850
2850
+ 0.74
6581
2035
+ 0.65
6581
8341
+ 0.61
2850
9935
+ 0.57
6581
  
High negative correlations   
2850
- 0.84
2002A
2035
- 0.64
2002A
2002A
- 0.62
6581
8341
- 0.42
2002A
9935
- 0.41
2002A
8341
- 0.38
3416

Risk-Adjusted Indicators

There is a big difference between GeneFerm Stock performing well and GeneFerm Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze GeneFerm Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

GeneFerm Biotechnology Competitive Analysis

The better you understand GeneFerm Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, GeneFerm Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across GeneFerm Biotechnology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
1796 6581 3416 2002A 2850 8341 6561 9935 2035
 0.89 
 49.95 
GeneFerm
 1.79 
 110.00 
Taiwan
 0.98 
 151.00 
WinMate
 0.36 
 42.00 
China
 1.19 
 99.30 
Shinkong
 2.24 
 91.80 
Sunny
 0.59 
 513.00 
Chief
 3.41 
 31.20 
Ching
 0.61 
 33.20 
Tang
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Weak
Weak
OK
Very Weak
OK
Very Weak
Very Weak
Weak
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Below Average
Low
Low
Low
Below Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Hold
Hold
Hold
Cautious Hold
Strong Sell
Cautious Hold
Current Ratio
1.98
0.86
1.66
1.1
8.91
1.15
N/A
1.38
N/A
Net Asset
1.32 B
4.41 B
3.53 B
687.99 B
43.89 B
9.73 B
5.49 B
6.13 B
20.15 B
Profit Margin
0.15
0.38
0.16
0.0834
0.11
0.25
0.26
0.0371
0.0245
EBITDA
123.07 M
922.01 M
493.55 M
118.9 B
1.87 B
1.71 B
1.07 B
376.88 M
1.88 B
Operating Margin
0.17
0.47
0.17
0.1
0.0997
0.32
0.33
0.0234
0.0185
Current Valuation
2.48 B
9.84 B
5.51 B
661.01 B
5.07 B
23.52 B
19.26 B
6.87 B
17.96 B
Price To Book
2.94
2.58
2.56
2.22
1.05
6.17
6.47
1.31
1.98
Five Year Return
N/A
N/A
4.95
3.5
5.06
2.5
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
100.13 B
4.75 B
812 M
N/A
(698 M)
N/A
Current Asset
N/A
N/A
N/A
121.65 B
16.4 B
1.26 B
N/A
1.49 B
N/A
Beta
0.89
0.85
0.2
0.74
0.42
0.38
-0.12
0.62
0.29
Number Of Employees
12
17
17
64
1.65 K
15
9
13
659
Shares Outstanding
41.46 M
111.27 M
73.2 M
38.27 M
315.96 M
111.5 M
70.74 M
168.62 M
350 M
Cash Flow From Operations
112.23 M
827.15 M
370.31 M
71.3 B
1.7 B
1.27 B
887.23 M
223.28 M
430.64 M
Annual Yield
0.0139
0.0407
0.0525
0.0668
0.0632
0.0479
0.0316
0.0289
N/A
Total Debt
31.25 M
N/A
494.89 M
103.17 B
20.31 M
4.2 B
N/A
2.26 B
6.35 B
Return On Equity
0.12
0.27
0.18
0.12
0.14
0.3
0.26
0.0926
0.0668
Z Score
61.8
N/A
7.2
2.4
N/A
2.4
N/A
0.6
0.6
Return On Asset
0.0534
0.18
0.08
0.0439
0.0259
0.0776
0.11
0.012
0.0095
Book Value Per Share
19.63
36.85
32.56
21.13
45.48
27.55
43.44
13.55
16.29
Current Liabilities
N/A
N/A
N/A
140.04 B
1.92 B
600 M
N/A
2.16 B
N/A
Total Asset
1.32 B
4.41 B
3.53 B
687.99 B
43.89 B
9.73 B
5.49 B
6.13 B
20.15 B
Debt To Equity
0.72
0.09
0.23
70.7
0.1
39.7
N/A
106.2
N/A
Last Dividend Paid
N/A
4.0
4.5
3.1
3.2
8.0
9.3
0.26
N/A
Target Price
N/A
N/A
100.0
N/A
28.6
162.0
N/A
N/A
N/A
Shares Owned By Institutions
N/A
1.61
0.71
N/A
15.9
12.2
14.4
4.41
29.4
Market Capitalization
3.22 B
11.05 B
6.3 B
486.09 B
16.21 B
18.45 B
20.73 B
2.98 B
11.18 B
Price To Earning
53.28
18.49
24.03
32.05
8.63
35.03
N/A
18.09
N/A
Price To Sales
4.16
3.99
2.33
0.94
0.83
5.38
6.8
0.54
0.75
Net Income
57.41 M
564.87 M
364.71 M
62.05 B
2.25 B
944.91 M
686.57 M
77.93 M
1.59 B
Earnings Per Share
2.18
9.08
5.26
2.59
6.41
8.57
11.14
1.19
1.05
Shares Owned By Insiders
57.17
83.94
59.77
N/A
33.98
44.17
66.67
31.49
53.8
Revenue
522.33 M
1.85 B
2.5 B
468.33 B
18.46 B
3.35 B
2.8 B
4.97 B
16.81 B
Working Capital
N/A
N/A
N/A
(18.39 B)
14.48 B
657 M
N/A
(665 M)
N/A
Cash And Equivalents
619.1 M
567.54 M
1.21 B
31.6 B
16.28 B
1.18 B
N/A
267.76 M
N/A
Cash Per Share
15.32
5.1
16.71
2.05
51.53
10.56
N/A
1.58
N/A
Gross Profit
192.65 M
1.01 B
838.11 M
98.68 B
6.57 B
1.75 B
1.26 B
778.69 M
1.97 B
Day Typical Price
50.13
110.5
152.67
41.9
99.7
92.57
521.0
31.52
33.17
Accumulation Distribution
0.0109
0.0135
0.0321
0.0071
0.0119
0.0244
0.0447
0.0295
0.003
Market Facilitation Index
0.55
1.5
5.0
0.3
1.2
2.3
24.0
0.95
0.1
Daily Balance Of Power
(0.82)
(1.33)
(0.30)
0.5
(1.00)
(0.91)
0.125
(1.16)
2.0
Period Momentum Indicator
(0.45)
(2.00)
(1.50)
0.15
(1.20)
(2.10)
3.0
(1.10)
0.2
Rate Of Daily Change
0.99
0.98
0.99
1.0
0.99
0.98
1.01
0.97
1.01
Day Median Price
50.23
110.75
153.5
41.85
99.9
92.95
525.0
31.67
33.15
Price Action Indicator
(0.50)
(1.75)
(3.25)
0.22
(1.20)
(2.20)
(10.50)
(1.02)
0.15
Coefficient Of Variation
1315.63
4270.39
1114.33
(1,123)
1112.6
(5,695)
2489.16
2437.51
1182.04
Mean Deviation
1.28
1.25
1.1
0.2034
0.8576
1.38
1.45
1.98
0.4243
Jensen Alpha
0.1549
0.0281
0.0653
(0.03)
0.0622
(0.12)
0.0409
0.0705
0.0324
Total Risk Alpha
(0.15)
(0.27)
(0.11)
(0.08)
(0.08)
(0.33)
(0.27)
(0.32)
(0.06)
Sortino Ratio
0.0088
(0.04)
0.0098
N/A
(0.01)
N/A
(0.02)
(0)
(0.07)
Downside Variance
2.73
4.41
3.43
N/A
1.77
N/A
4.16
7.23
0.8462
Standard Deviation
1.84
2.06
1.6
0.2769
1.18
1.92
2.35
2.82
0.6871
Kurtosis
1.64
7.56
1.97
2.07
1.25
1.5
7.39
2.32
5.25
Potential Upside
3.65
2.27
3.02
0.3584
1.82
3.22
3.63
6.19
1.09
Treynor Ratio
(0.60)
0.4342
0.2257
1.81
0.3266
(0.07)
0.2238
0.3464
0.3531
Maximum Drawdown
10.82
12.95
6.73
1.66
6.85
10.46
14.39
15.2
4.46
Variance
3.39
4.25
2.56
0.0767
1.4
3.7
5.53
7.95
0.4721
Market Risk Adjusted Performance
(0.59)
0.4442
0.2357
1.82
0.3366
(0.06)
0.2338
0.3564
0.3631
Risk Adjusted Performance
0.0641
0.0242
0.074
(0.09)
0.0724
(0.01)
0.0375
0.0387
0.0637
Skewness
0.1351
1.74
0.0324
(0.53)
(0.23)
0.6021
1.87
1.01
(1.14)
Semi Deviation
1.43
1.58
1.36
N/A
1.09
N/A
1.76
2.4
0.6848
Information Ratio
0.0079
(0.04)
0.0114
(0.54)
(0.02)
(0.08)
(0.01)
(0)
(0.1)
Value At Risk
(2.50)
(2.98)
(2.47)
(0.36)
(1.80)
(3.23)
(2.52)
(3.81)
(1.07)
Expected Short fall
(1.77)
(1.58)
(1.40)
N/A
(0.99)
N/A
(1.69)
(2.09)
(0.48)
Downside Deviation
1.65
2.1
1.85
N/A
1.33
N/A
2.04
2.69
0.9199
Semi Variance
2.04
2.5
1.85
N/A
1.18
N/A
3.11
5.76
0.4689

GeneFerm Biotechnology Competition Performance Charts

Five steps to successful analysis of GeneFerm Biotechnology Competition

GeneFerm Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by GeneFerm Biotechnology in relation to its competition. GeneFerm Biotechnology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of GeneFerm Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact GeneFerm Biotechnology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to GeneFerm Biotechnology, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your GeneFerm Biotechnology position

In addition to having GeneFerm Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cancer Fighters Thematic Idea Now

Cancer Fighters
Cancer Fighters Theme
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for GeneFerm Stock Analysis

When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY